Cellular Therapies: Revolutionizing Cancer Therapy
Part 2: CTL019 Therapy in Chronic Lymphocytic Leukemia


Related Videos (117)

In this second of four videos on the topic of cellular therapies for the hematologic malignancies, Carl H June, MD,  describes the five-step design of CAR T cell therapy, from blood donation to modified T cell infusion, and reviews the phase 1 study of CTL019 (CAR T) therapy in patients with refractory, relapsed chronic lymphocytic leukemia, as well as outcomes for this trial and the characteristics of patients with long term durable remission.

To view other parts of this program:

Part 1: Adoptive Cell Therapy - An Introduction

Part 3: CTL019 in Relapsed Refractory Pediatric Acute Lymphoblastic Leukemia

Part 4: Adoptive Cell Therapy - Lessons Learned, Issues and the Future


Penn PhysicianLink®

Penn PhysicianLink® is an exclusive program that helps all referring physicians connect with Penn Medicine. This comprehensive package of support services expedites and facilitates direct physician communication for patient consults, referrals and transfers.

Learn more about Penn PhysicianLink®